GRAFT VS HOST DISEASE
Clinical trials for GRAFT VS HOST DISEASE explained in plain language.
Never miss a new study
Get alerted when new GRAFT VS HOST DISEASE trials appear
Sign up with your email to follow new studies for GRAFT VS HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Doctors test if less medication can prevent deadly transplant complication
Disease control CompletedThis study looked at whether giving liver transplant patients a lower dose of anti-rejection drugs could help prevent a rare but deadly complication called graft-versus-host disease (GVHD). Researchers followed 100 adult transplant recipients for a year to see if this approach re…
Matched conditions: GRAFT VS HOST DISEASE
Sponsor: Methodist Health System • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
New hope for transplant patients with Treatment-Resistant complications
Disease control CompletedThis study tested whether the drug pomalidomide could help control chronic graft-versus-host disease (GvHD) in people who didn't respond to standard steroid treatments. GvHD is a serious complication that can occur after a stem cell transplant, where the donor's immune cells atta…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:33 UTC
-
New hope for kids battling dangerous transplant complication
Disease control CompletedThis study tested whether adding the drug ruxolitinib to standard steroid treatment could help children with moderate to severe chronic graft vs host disease (cGvHD). cGvHD is a serious complication where donor immune cells attack the patient's body after a stem cell transplant. …
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC
-
New hope to stop deadly transplant complication
Disease control CompletedThis study tested if adding a drug called abatacept to the standard two-drug regimen could better prevent severe Graft vs Host Disease (GvHD) in patients receiving a stem cell transplant from an unrelated donor. GvHD is a dangerous condition where the donor's immune cells attack …
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New drug tested to stop dangerous transplant complication
Prevention CompletedThis study tested whether a drug called obinutuzumab could prevent chronic Graft-vs-Host Disease (cGVHD) in patients who received a stem cell transplant. cGVHD is a serious condition where the donor's immune cells attack the recipient's body. In this trial, 181 adult transplant p…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Prevention
Last updated Apr 01, 2026 14:42 UTC
-
New hope to stop dangerous transplant complication
Prevention CompletedThis study tested if adding a drug called pacritinib to standard anti-rejection medicines could better prevent graft-versus-host disease (GVHD) after a stem cell transplant. It involved 40 patients with blood cancers who received matched donor transplants. Researchers measured in…
Matched conditions: GRAFT VS HOST DISEASE
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Prevention
Last updated Mar 27, 2026 12:38 UTC